Research and Investment Prospect of Human Vaccine Industry in China, 2014-2018
|出版日期||內容資訊||英文 56 Pages
|中國的人類用疫苗產業的調查、投資預測 Research and Investment Prospect of Human Vaccine Industry in China, 2014-2018|
|出版日期: 2014年12月12日||內容資訊: 英文 56 Pages||
Research and Investment Prospect of Human Vaccine Industry in China, 2014-2018, mainly studies the market, competition pattern and segmentations of human vaccine industry in China and analyzes the industry chain, import & export and key enterprises of human vaccine in China. This report analyzes the business performances of 7 key enterprises, including Beijing Tiantan Biological Products Co., Ltd, ChongQing ZhiFei Biological Products Co., Ltd, Walvax Biotechnology Co., Ltd, Liaoning Chengda Co., Ltd (LCD) etc.
As one of powerful vaccine manufacturing countries in world, China has 42 vaccine manufacturers with approval license. In 2013, the total of lot release quantity of vaccines was about 755 million doses, increasing by 0.53% over the 751 million doses in 2012. Vaccine manufacturers mainly consist of state-owned enterprises, private enterprises and foreign-funded enterprises in China. Seeing from the lot release quantity of vaccine in 2013, the state-owned enterprises still take the leading position in vaccine market, with market shares of 62%, followed by private enterprises and foreign-funded enterprises successively, with market shares of 33.77% and 4.23% respectively.
Most of market of type I vaccines is still dominated by state-owned enterprises, including 6 largest institutes of China National Biotec-Group Company Limited and Changchun Keygen Biological Products Co., Ltd. Private enterprises take half of market shares of type II vaccines, the representative enterprises include: ChongQing ZhiFei Biological Products Co., Ltd, and Walvax Biotechnology Co., Ltd etc. While the international enterprises have definite advantages in respects of high-end vaccines and multivalent vaccines, taking pneumococcal vaccines for instance, only one conjugate vaccine is available, say: Pneumococcal 7-Valent Conjugate Vaccine produced by Pfizer. Although, at present, several enterprises are conducting studies on pneumococcal conjugate vaccines, it is still long to launch on the market, with huge uncertainties.
In 2014-2018, the average growth rate of vaccine in China will maintain at 16%-18%. The main driving factors include: implement of national vaccine immunization plan, increasing receptivity of vaccine by people, rising trend of initiative vaccination and increase of type III vaccines application etc. It can be expected that the market scale of vaccine will hit CNY 40.5 billion in 2018.